Richard Chong Joins XGS Energy as Chief Financial Officer

XGS Energy, Inc. (XGS), a developer of next-generation geothermal power systems, today announced the appointment of Richard Chong as Chief Financial Officer. Richard brings over 25 years of energy finance leadership, spanning public and private equity and credit, project finance, and strategic planning.

InterVenn Appoints Industry Leaders Alec Ford and Mitch Levine to Board of Directors

InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, today announced the appointment of Alec Ford and Mitch Levine to the company’s Board of Directors. These strategic appointments come as InterVenn focuses on the next phase of its growth: advancing the commercialization of glycoproteomic diagnostics. The company is developing glycoproteomic diagnostic solutions designed to support more informed clinical decision-making across complex diseases.

Exyn Announces Pricing of Initial Public Offering

Exyn Technologies, Inc. (“Exyn” or the “Company”), a pioneer in multi-platform robotic autonomy for complex, GPS-denied environments, today announced the pricing of its initial public offering (the “Offering”) of 2,500,000 units with each unit consisting of one share of its common stock (the “Common Stock”) and one warrant to purchase one share of its common stock (the “Warrants”) at a public offering price of $7.75 per unit, for total gross proceeds of approximately $19.4 million, before deducting underwriting discounts and commissions and other offering expenses payable by Exyn. All of the shares of Common Stock and Warrants are being offered by the Company. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 375,000 shares of its Common Stock and/or 375,000 Warrants at the public offering price, less the underwriting discounts and commissions.

GelSight Introduces GelSight® Mobile™ 4.4 Software to Streamline Every Step of the Inspection Workflow

GelSight Mobile 4.4 builds on the platform’s evolution from a powerful measurement device into a guided, decision-ready inspection system. This release introduces enhanced offset output statistics, animated step-by-step calibration guidance for the Modulus™ sensor, customizable PDF report templates, stacked routines in Operator mode, PLY file export and more to collectively reduce training time, inspection time, and post-processing effort.

Niron Magnetics Awarded $400,000 Minnesota Grant To Support Workforce Training

Niron Magnetics, the leading manufacturer of rare-earth-free Iron Nitride permanent magnets, today announced it has been awarded $400,000 through the Minnesota Job Skills Partnership (MJSP) grant program, administered by the Minnesota Department of Employment and Economic Development (DEED). The funding will support workforce training as the company enters a new phase of growth and continues transitioning to high-volume manufacturing.

6K Additive Appoints Manufacturing Veteran Brandon Davis as Chief Operating Officer

6K Additive, Inc. (ASX: 6KA) a leader in the domestic production of high-performance metal powders, today announced the appointment of Brandon Davis as Chief Operating Officer. Davis, a high-impact manufacturing executive with over two decades of experience, will oversee the company’s global operations, including metal powder production and alloy additions.

From Army Depot to Factory Floor: GelSight’s Modulus Reaches 100-Units Sold Milestone

Named for the modular probe architecture that emerged from Army requirements, the Modulus was originally developed under Contract W911W6-23-C-0002 with DEVCOM Aviation & Missile Center (DEVCOM AvMC). It is now deployed across commercial aerospace, manufacturing, and quality control applications where surface integrity is critical to safety and performance.

ImmunoScape Presents Data on Significant, Selective In-Vivo Expansion of Cell Therapy Product at AACR Annual Meeting

ImmunoScape Pte. Ltd., a spin-out of A*STAR backed by Amgen Ventures and EDBI that is developing next-generation TCR-based cancer immunotherapies, today announced the presentation of compelling new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2026. The poster, titled “A novel ‘Seed-and-Boost’ immunotherapy drives potent TCR-T cell expansion, tumor infiltration, and durable tumor control,” was presented on Monday, April 20, 2026 by Michael Fehlings, PhD, Co-Founder and CEO of ImmunoScape.